retatrutide triple agonist obesity trial hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide—A Game Changer in Obesity
Description
DRM reports receiving research support from Janssen, serving on advisory boards and as a consultant for Novo Nordisk, Novartis, Eli Lilly, Sanofi-Aventis, Janssen and Servier, and giving lectures for Novo Nordisk, Servier, Sanofi-Aventis, Eli Lilly, Novartis and Janssen
Ozempic may support weight loss by helping reduce appetite, slow stomach emptying, and improve blood sugar control
As a unimolecular triple agonist, it targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors
Diabetes, Metabolic Syndrome
Our robust IT infrastructure provides advanced computing resources for secure data storage, processing, and analysis
